Gloucester Pharmaceuticals Report issue

Contributed to NME For profit Phase 2
Founded: Cambridge MA United States (2003)
Status: Acquired by Celgene (2009) → now Bristol-Myers Squibb (2019)

Organization Overview

First Clinical Trial
2003
NCT00106613
First Marketed Drug
2009
romidepsin (istodax)
First NDA Approval
2009
romidepsin (istodax)
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Gloucester Pharmaceuticals, Inc.

Active Ingredients

Marketed Drugs (1)

romidepsin (istodax) (2009 NDA)

Drugs in Phase 2 Trials (1)

romidepsin (istodax) (3 trials)

Indications

Approved Indications


 

Lymphoma, T-Cell, Cutaneous

Lymphoma, T-Cell, Peripheral

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Neoplasm Metastasis (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1